Precision immunotherapy of moderate-to-severe atopic dermatitis mice using mycophenolate mofetil nanoparticles
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2025.115987 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Siwei Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China; Key Laboratory of Auxiliary Chemistry and Technology fo…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Mycophenolic Acid, Nanoparticles, Immunotherapy. Die Arbeit nennt 73 Literaturangaben. Gefördert von: Shaanxi University of Science and Technology, Natural Science Basic Research Program of Shaanxi Province, Xi'an Medical University.
Abstract (Originalsprache)
Mycophenolate mofetil (MMF) shows significant potential for precision immunotherapy in moderate to severe atopic dermatitis (AD). However, its clinical application is limited by inadequate delivery efficiency and dose related toxicities. Herein, we propose a straightforward and effective drug delivery strategy that involves coating MMF with polydopamine (PDA) to fabricate MMF nanoparticles (MMF NPs). A systematic investigation of their therapeutic efficacy and mechanism of action was also conducted in the AD model mice. Due to surface hydrophilicity and nanoscale effects mediated by PDA, MMF NPs demonstrate excellent stability, high drug loading capacity, and optimized pharmacokinetics. The prolonged circulation time and enhanced permeability retention effect reduce both toxicity and susceptibility to infections associated with MMF, which leads to a marked improvement in the therapeutic efficacy of AD. Finally, MMF NPs achieve precise immunotherapy through the synergistic effect by balancing systemic immunity and precisely targeting the local inflammatory microenvironment. This study not only presents a safe and effective treatment strategy for AD but also introduces a novel delivery approach for the clinical application of MMF in immune-mediated disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China; Key Laboratory of Auxiliary Chemistry and Technology for Chemical Industry, Ministry of Education, Shaanxi Collaborative Inno…
- Xi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Xi'an Medical University, Xi'an 710021, China; Modern Research…
- Xi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Xi'an Medical University, Xi'an 710021, China; School of Clini…
- Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China; Xi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention…
- Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, China. Electronic address: 15619239851@163.com.
Förderung
- Shaanxi University of Science and Technology
- Natural Science Basic Research Program of Shaanxi Province
- Xi'an Medical University
Zitieren
APA
Sun, S., Qi, J., Zhou, Y., Li, K., Rong, Y., Bi, J., Hu, W., Luan, J., & Li, X. (2026). Precision immunotherapy of moderate-to-severe atopic dermatitis mice using mycophenolate mofetil nanoparticles. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115987
Vancouver
Sun S, Qi J, Zhou Y, Li K, Rong Y, Bi J, et al. Precision immunotherapy of moderate-to-severe atopic dermatitis mice using mycophenolate mofetil nanoparticles. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2025.115987
BibTeX
@article{Sun2026,
author = {Sun, Siwei and Qi, Jiale and Zhou, Yun and Li, Ke and Rong, Yu and Bi, Jiao and Hu, Weixin and Luan, Jing and Li, Xueping},
title = {Precision immunotherapy of moderate-to-severe atopic dermatitis mice using mycophenolate mofetil nanoparticles},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2025.115987}
}
EUVIMED